Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** AMENDED AND RESTATED TECHNOLOGY License AGREEMENTTechnology License Agreement • January 13th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • Hong Kong
This Amended and Restated Technology License Agreement (the “Agreement”) is entered into as of December 21, 2015 (the “Execution Date”) between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China (“PRC”) and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT” or “Licensee”); and Oramed Pharmaceuticals Inc., a Delaware corporation and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (collectively referred to as “Oramed”). HTIT and Oramed are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
